# ACRV — Acrivon Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ACRV  
**Sources:** 17  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-acrv-acrivon-therapeutics-inc-catalysts-narrative-risks-5824

---

# Acrivon Therapeutics, Inc. (ACRV) — Research Summary (as of 2026-10-03)

## Company Snapshot
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company developing precision medicines for cancer patients using its proprietary Acrivon Predictive Precision Proteomics (AP3) generative phosphoproteomics platform [[2]](https://finance.yahoo.com/healthcare/articles/acrivon-therapeutics-present-2026-cantor-120000661.html), [[6]](https://www.marketbeat.com/stocks/NASDAQ/ACRV/), [[9]](https://stockanalysis.com/stocks/acrv/). The company was founded in 2018 and is led by CEO Peter Blume-Jensen, M.D., Ph.D. [[2]](https://finance.yahoo.com/healthcare/articles/acrivon-therapeutics-present-2026-cantor-120000661.html), [[9]](https://stockanalysis.com/stocks/acrv/). As of the Oct 2, 2026 close, the stock traded at ~$1.99 with a market capitalization of ~$85.3 million [[6]](https://www.marketbeat.com/stocks/NASDAQ/ACRV/), [[9]](https://stockanalysis.com/stocks/acrv/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-acrv-acrivon-therapeutics-inc-catalysts-narrative-risks-5824 (free to sign up)._
